Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.82
GILD's Cash to Debt is ranked higher than
53% of the 1428 Companies
in the Global Biotechnology industry.

( Industry Median: 39.38 vs. GILD: 0.82 )
GILD' s 10-Year Cash to Debt Range
Min: 0.23   Max: 3021.78
Current: 0.82

0.23
3021.78
Equity to Asset 0.45
GILD's Equity to Asset is ranked higher than
59% of the 1094 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. GILD: 0.45 )
GILD' s 10-Year Equity to Asset Range
Min: 0.39   Max: 0.94
Current: 0.45

0.39
0.94
Interest Coverage 37.05
GILD's Interest Coverage is ranked higher than
51% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GILD: 37.05 )
GILD' s 10-Year Interest Coverage Range
Min: 5.85   Max: 2509.2
Current: 37.05

5.85
2509.2
F-Score: 8
Z-Score: 7.78
M-Score: -1.76
WACC vs ROIC
8.33%
73.96%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 61.33
GILD's Operating margin (%) is ranked higher than
99% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -96.70 vs. GILD: 61.33 )
GILD' s 10-Year Operating margin (%) Range
Min: -1185.19   Max: 61.33
Current: 61.33

-1185.19
61.33
Net-margin (%) 48.62
GILD's Net-margin (%) is ranked higher than
98% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. GILD: 48.62 )
GILD' s 10-Year Net-margin (%) Range
Min: -1014.81   Max: 48.62
Current: 48.62

-1014.81
48.62
ROE (%) 86.63
GILD's ROE (%) is ranked higher than
99% of the 1311 Companies
in the Global Biotechnology industry.

( Industry Median: -30.34 vs. GILD: 86.63 )
GILD' s 10-Year ROE (%) Range
Min: -49.14   Max: 90.32
Current: 86.63

-49.14
90.32
ROA (%) 41.62
GILD's ROA (%) is ranked higher than
99% of the 1436 Companies
in the Global Biotechnology industry.

( Industry Median: -25.14 vs. GILD: 41.62 )
GILD' s 10-Year ROA (%) Range
Min: -30.31   Max: 42.28
Current: 41.62

-30.31
42.28
ROC (Joel Greenblatt) (%) 457.93
GILD's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -359.85 vs. GILD: 457.93 )
GILD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -127.04   Max: 484.37
Current: 457.93

-127.04
484.37
Revenue Growth (3Y)(%) 41.70
GILD's Revenue Growth (3Y)(%) is ranked higher than
95% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. GILD: 41.70 )
GILD' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 71.8
Current: 41.7

0
71.8
EBITDA Growth (3Y)(%) 55.60
GILD's EBITDA Growth (3Y)(%) is ranked higher than
97% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. GILD: 55.60 )
GILD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -20.6   Max: 119
Current: 55.6

-20.6
119
EPS Growth (3Y)(%) 60.70
GILD's EPS Growth (3Y)(%) is ranked higher than
98% of the 803 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. GILD: 60.70 )
GILD' s 10-Year EPS Growth (3Y)(%) Range
Min: -20.6   Max: 153.3
Current: 60.7

-20.6
153.3
» GILD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

GILD Guru Trades in Q1 2014

Jim Simons 189,353 sh (New)
George Soros 50,000 sh (New)
John Burbank 3,619 sh (New)
Caxton Associates 50,000 sh (New)
Louis Moore Bacon 2,239,590 sh (+646.53%)
Ray Dalio 247,721 sh (+541.42%)
Steven Cohen 207,778 sh (+229.81%)
Paul Tudor Jones 10,805 sh (+35.11%)
Mario Gabelli 44,240 sh (+31.65%)
John Rogers 397,273 sh (+22.50%)
Mariko Gordon 18,089 sh (+17.07%)
Pioneer Investments 3,349,807 sh (+16.11%)
RS Investment Management 180,214 sh (+10.91%)
Julian Robertson 345,320 sh (+7.91%)
David Rolfe 1,907,287 sh (+5.90%)
Jean-Marie Eveillard 400 sh (unchged)
Paul Tudor Jones 75,000 sh (unchged)
Caxton Associates 60,000 sh (unchged)
Daniel Loeb Sold Out
Stanley Druckenmiller Sold Out
John Griffin Sold Out
Ronald Muhlenkamp 192,015 sh (-0.40%)
Ken Fisher 601,758 sh (-40.46%)
Vanguard Health Care Fund 2,713,300 sh (-41.41%)
Jeremy Grantham 516,946 sh (-84.74%)
» More
Q2 2014

GILD Guru Trades in Q2 2014

Ken Heebner 1,710,000 sh (New)
Joel Greenblatt 466,853 sh (New)
Alan Fournier 2,070,000 sh (New)
Ken Fisher 975,483 sh (+62.11%)
John Rogers 638,734 sh (+60.78%)
Ray Dalio 349,821 sh (+41.22%)
Julian Robertson 443,911 sh (+28.55%)
Pioneer Investments 3,899,022 sh (+16.40%)
Mario Gabelli 49,170 sh (+11.14%)
RS Investment Management 192,614 sh (+6.88%)
John Burbank 3,774 sh (+4.28%)
Caxton Associates 100,000 sh (unchged)
Jean-Marie Eveillard 400 sh (unchged)
George Soros Sold Out
David Rolfe Sold Out
Caxton Associates Sold Out
Louis Moore Bacon Sold Out
Jim Simons 166,648 sh (-11.99%)
Paul Tudor Jones 9,304 sh (-13.89%)
Ronald Muhlenkamp 144,715 sh (-24.63%)
Mariko Gordon 11,654 sh (-35.57%)
Vanguard Health Care Fund 1,633,700 sh (-39.79%)
Jeremy Grantham 10,600 sh (-97.95%)
» More
Q3 2014

GILD Guru Trades in Q3 2014

Dodge & Cox 4,800 sh (New)
David Dreman 2,388 sh (New)
Stanley Druckenmiller 217,500 sh (New)
Louis Moore Bacon 11,734 sh (New)
Paul Tudor Jones 30,245 sh (+225.08%)
John Burbank 12,073 sh (+219.90%)
Ronald Muhlenkamp 206,350 sh (+42.59%)
Joel Greenblatt 664,223 sh (+42.28%)
John Rogers 643,896 sh (+0.81%)
Pioneer Investments 3,536,065 sh (unchged)
Jean-Marie Eveillard 400 sh (unchged)
Julian Robertson 443,911 sh (unchged)
Jim Simons Sold Out
Ken Heebner 1,560,000 sh (-8.77%)
Alan Fournier 1,861,000 sh (-10.10%)
Mariko Gordon 10,366 sh (-11.05%)
Mario Gabelli 42,600 sh (-13.36%)
RS Investment Management 151,879 sh (-21.15%)
Ken Fisher 763,423 sh (-21.74%)
Ray Dalio 241,521 sh (-30.96%)
Jeremy Grantham 6,700 sh (-36.79%)
Vanguard Health Care Fund 379,200 sh (-76.79%)
» More
Q4 2014

GILD Guru Trades in Q4 2014

Steven Cohen 1,061,100 sh (New)
Jim Simons 941,400 sh (New)
Leon Cooperman 612,500 sh (New)
Jean-Marie Eveillard 1,315,088 sh (+328672.00%)
Paul Tudor Jones 109,372 sh (+261.62%)
John Burbank 37,750 sh (+212.68%)
Ray Dalio 537,321 sh (+122.47%)
Joel Greenblatt 1,009,462 sh (+51.98%)
RS Investment Management 190,460 sh (+25.40%)
John Rogers 802,803 sh (+24.68%)
Julian Robertson 533,911 sh (+20.27%)
Alan Fournier 2,141,000 sh (+15.05%)
Ronald Muhlenkamp 218,945 sh (+6.10%)
Ken Fisher 771,501 sh (+1.06%)
Mario Gabelli 42,600 sh (unchged)
Louis Moore Bacon 50,000 sh (unchged)
Jean-Marie Eveillard 1,200 sh (unchged)
Mariko Gordon Sold Out
Vanguard Health Care Fund Sold Out
Stanley Druckenmiller Sold Out
David Dreman Sold Out
Louis Moore Bacon Sold Out
Ken Heebner Sold Out
Dodge & Cox 4,510 sh (-6.04%)
Pioneer Investments 3,180,990 sh (-10.04%)
Jeremy Grantham 4,600 sh (-31.34%)
» More
» Details

Insider Trades

Latest Guru Trades with GILD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Gilead Sciences Inc

Weekly CFO Sells Highlight: Affiliated Managers Group Inc., Gilead Sciences Inc., L-3 Communications Holdings Inc.
According to GuruFocus Insider Data, the recent CFO sales were: Affiliated Managers Group Inc., Gilead Sciences Inc. and L-3 Communications Holdings Inc. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 13.80
GILD's P/E(ttm) is ranked higher than
99% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GILD: 13.80 )
GILD' s 10-Year P/E(ttm) Range
Min: 9.69   Max: 45.41
Current: 13.8

9.69
45.41
Forward P/E 9.44
GILD's Forward P/E is ranked higher than
98% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GILD: 9.44 )
N/A
PE(NRI) 13.60
GILD's PE(NRI) is ranked higher than
99% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GILD: 13.60 )
GILD' s 10-Year PE(NRI) Range
Min: 9.68   Max: 45.49
Current: 13.6

9.68
45.49
P/B 10.00
GILD's P/B is ranked higher than
52% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. GILD: 10.00 )
GILD' s 10-Year P/B Range
Min: 4.16   Max: 18.59
Current: 10

4.16
18.59
P/S 6.86
GILD's P/S is ranked higher than
80% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 36.81 vs. GILD: 6.86 )
GILD' s 10-Year P/S Range
Min: 3.48   Max: 14.41
Current: 6.86

3.48
14.41
PFCF 13.70
GILD's PFCF is ranked higher than
98% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GILD: 13.70 )
GILD' s 10-Year PFCF Range
Min: 8.33   Max: 59.09
Current: 13.7

8.33
59.09
POCF 12.91
GILD's POCF is ranked higher than
98% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GILD: 12.91 )
GILD' s 10-Year POCF Range
Min: 8.01   Max: 52.27
Current: 12.91

8.01
52.27
EV-to-EBIT 10.00
GILD's EV-to-EBIT is ranked higher than
99% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GILD: 10.00 )
GILD' s 10-Year EV-to-EBIT Range
Min: -103.9   Max: 473.4
Current: 10

-103.9
473.4
PEG 0.50
GILD's PEG is ranked higher than
100% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GILD: 0.50 )
GILD' s 10-Year PEG Range
Min: 0.37   Max: 4.23
Current: 0.5

0.37
4.23
Shiller P/E 38.50
GILD's Shiller P/E is ranked higher than
97% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GILD: 38.50 )
GILD' s 10-Year Shiller P/E Range
Min: 17.87   Max: 1840.8
Current: 38.5

17.87
1840.8
Current Ratio 3.07
GILD's Current Ratio is ranked higher than
65% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. GILD: 3.07 )
GILD' s 10-Year Current Ratio Range
Min: 1.09   Max: 18.65
Current: 3.07

1.09
18.65
Quick Ratio 2.83
GILD's Quick Ratio is ranked higher than
66% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. GILD: 2.83 )
GILD' s 10-Year Quick Ratio Range
Min: 0.83   Max: 18.65
Current: 2.83

0.83
18.65
Days Inventory 177.33
GILD's Days Inventory is ranked higher than
83% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GILD: 177.33 )
GILD' s 10-Year Days Inventory Range
Min: 148.53   Max: 405.59
Current: 177.33

148.53
405.59
Days Sales Outstanding 67.97
GILD's Days Sales Outstanding is ranked higher than
81% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 134.01 vs. GILD: 67.97 )
GILD' s 10-Year Days Sales Outstanding Range
Min: 65.89   Max: 115.9
Current: 67.97

65.89
115.9

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 49.10
GILD's Price/Tangible Book is ranked lower than
62% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 10.90 vs. GILD: 49.10 )
GILD' s 10-Year Price/Tangible Book Range
Min: 2.08   Max: 131.22
Current: 49.1

2.08
131.22
Price/DCF (Projected) 2.10
GILD's Price/DCF (Projected) is ranked higher than
97% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GILD: 2.10 )
GILD' s 10-Year Price/DCF (Projected) Range
Min: 0.77   Max: 20.81
Current: 2.1

0.77
20.81
Price/Median PS Value 0.80
GILD's Price/Median PS Value is ranked higher than
93% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. GILD: 0.80 )
GILD' s 10-Year Price/Median PS Value Range
Min: 0.43   Max: 4.34
Current: 0.8

0.43
4.34
Price/Peter Lynch Fair Value 0.60
GILD's Price/Peter Lynch Fair Value is ranked higher than
100% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GILD: 0.60 )
GILD' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.43   Max: 9.13
Current: 0.6

0.43
9.13
Price/Graham Number 5.30
GILD's Price/Graham Number is ranked higher than
91% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GILD: 5.30 )
GILD' s 10-Year Price/Graham Number Range
Min: 1.71   Max: 8.74
Current: 5.3

1.71
8.74
Earnings Yield (Greenblatt) 9.80
GILD's Earnings Yield (Greenblatt) is ranked higher than
98% of the 1389 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. GILD: 9.80 )
GILD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 15
Current: 9.8

0.2
15
Forward Rate of Return (Yacktman) 27.42
GILD's Forward Rate of Return (Yacktman) is ranked higher than
89% of the 167 Companies
in the Global Biotechnology industry.

( Industry Median: 15.43 vs. GILD: 27.42 )
GILD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.2   Max: 46.1
Current: 27.42

0.2
46.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, BIIB, CELG, CMXHY » details
Traded in other countries:GIS.Germany, GILD.Mexico, GILD.Switzerland,
Gilead Sciences Inc was incorporated in Delaware on June 22, 1987. The Company is a research-based biopharmaceutical company that discovers, develops and commercializes new medicines for different medical sectors. With each new discovery and experimental drug candidate, it seeks to improve the care of patients suffering from life-threatening diseases around the world. The Company's primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases such as hepatitis B and C and serious cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Australia. It markets products in the HIV/AIDS, liver diseases, respiratory and cardiovascular/metabolic therapeutic areas. The Company's products comprise Truvada is an oral formulation dosed once a day as part of combination therapy to treat human immunodeficiency virus infection in adults. Atripla is an oral formulation dosed once a day for the treatment of HIV infection in adults. Viread is an oral formulation of a nucleotide analogue reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. Emtriva is an oral formulation of a nucleoside analogue reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. Hepsera is an oral formulation of a nucleotide analogue polymerase inhibitor, dosed once a day to treat chronic hepatitis B. AmBisome is a proprietary liposomal formulation of amphotericin B, an antifungal agent to treat serious invasive fungal infections caused by various fungal species. Letairis is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension in patients with WHO Class II or III symptoms to improve exercise capacity and delay clinical worsening. Ranexa is indicated for the treatment of chronic angina. Vistide is an antiviral medication for the treatment of cytomegalovirus retinitis in patients with AIDS. Cayston is an inhaled antibiotic as a treatment to improve respiratory systems in cystic fibrosis patients with Pseudomonas aeruginosa. The Company has U.S. and international commercial sales operations, with marketing subsidiaries in Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, the Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, Switzerland, Turkey, the United Kingdom and the United States. The Company sells and distributes Truvada, Viread, Emtriva, Hepsera and AmBisome in Asia, Australia, Europe, Latin America, the Middle East and New Zealand either through its commercial teams, third party distributors or corporate partners. The Company's products and development programs target a number of areas, including viral, fungal, respiratory and cardiovascular diseases. The Company's products compete with other available products based mainly on: efficacy; safety; tolerability; acceptance by doctors
» More Articles for GILD

Headlines

Articles On GuruFocus.com
AbbVie Focusing On Diversification Routes To Put Higher Sales Numbers On The Board Apr 24 2015 
Weekly CFO Sells Highlight: Gilead Sciences Inc, CarMax Inc, Anthem Inc. Apr 20 2015 
Current positions Apr 13 2015 
Prescription Data Offers Insight Into Gilead Sciences' Sales Apr 08 2015 
HealthCare Stocks That Can Make Investors Healthier Apr 08 2015 
Weekly CEO Sells Highlight: Sprouts Farmers Market, Lions Gate Entertainment, AMN Healthcare Service Apr 05 2015 
My starred stocks Apr 05 2015 
sales growth Apr 03 2015 
Gilead Experiencing Bumpy Ride Despite Strong Fundamentals Apr 03 2015 
UnitedHealth Planning Catamaran Corp’s Acquisition For $12.78 Billion Apr 02 2015 


More From Other Websites
4 Top-Rated Drugmakers Reporting Earnings This Week Apr 26 2015
Bristol-Myers says hepatitis C drug combination succeeds in study Apr 25 2015
Trusty Horses; Tools, Pizza and Shoes: Jim Cramer's Best Blogs Apr 25 2015
Gilead Announces Results From Studies Evaluating Sofosbuvir-Based Regimens in Chronic Hepatitis C... Apr 25 2015
Gilead Announces Results From Studies Evaluating Sofosbuvir-Based Regimens in Chronic Hepatitis C... Apr 25 2015
Cramer's weird Apple Watch moment Apr 24 2015
Biz Break: The 2015 SV150: Apple in command, Wall Street has demands Apr 24 2015
Merck Reports Encouraging Data on HCV Combo Candidate - Analyst Blog Apr 24 2015
Humana (HUM), Gilead Sciences (GILD), McKesson Corporation (MCK) Among Sivik Global’s Top... Apr 24 2015
AbbVie's HCV Cocktail Treatment Under FDA Priority Review - Analyst Blog Apr 24 2015
Bridgewater Increases Position in Microsoft Corporation Apr 24 2015
Midday Glance: Biotechnology companies Apr 24 2015
Gilead Sciences: Hepatitis-C Prescriptions Fall, So Does the Stock Apr 24 2015
Merck: Hepatitis C Treatment Shows 95% Cure Rate Apr 24 2015
Hobbled Earnings, And Kissing Purgatory 'Good Buy' Apr 24 2015
EU regulators warn against combining hep C drugs with amiodarone Apr 24 2015
EU regulators warn against combining hep C drugs with amiodarone Apr 24 2015
Merck says experimental Hepatitis C treatment shows 95% cure rate Apr 24 2015
Analyst: Biogen Will Miss On Tecfidera Sales; No Threat To Gilead's Harvoni Apr 24 2015
Merck oral hepatitis C regimen shows 95 pct cure rate Apr 24 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK